Literature DB >> 15138572

Differential PIAS3 expression in human malignancy.

Liming Wang1, Sipra Banerjee.   

Abstract

STAT3 mediated signaling pathways can be inhibited by PIAS3 (protein inhibitor of activated STAT3), which was recently found to regulate protein stability and function by its SUMO (small-ubiquitin like modifiers) ligase activity in promoting sumoylation of important nuclear proteins. Over-expression of PIAS3 can induce apoptosis in prostate cancer cell lines both in vitro and in vivo. Checking endogenous PIAS3 expression in various human specimens by immunohistochemistry, we report that basal amounts of PIAS3 exist in the nucleus in a majority of epithelial and endothelial cells. Increased PIAS3 expression was observed in 100/103 samples examined in a variety of human cancers including lung, breast, prostate, colon-rectum, and brain tumors. Differential PIAS3 expression and the specific patterns may be useful as a molecular marker of human cancer.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15138572

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  49 in total

1.  Protein inhibitor of activated STAT3 expression in lung cancer.

Authors:  Amy Kluge; Snehal Dabir; Ilse Vlassenbroeck; Rosana Eisenberg; Afshin Dowlati
Journal:  Mol Oncol       Date:  2011-03-30       Impact factor: 6.603

Review 2.  SUMO rules: regulatory concepts and their implication in neurologic functions.

Authors:  Mathias Droescher; Viduth K Chaugule; Andrea Pichler
Journal:  Neuromolecular Med       Date:  2013-08-30       Impact factor: 3.843

Review 3.  SUMO: a (oxidative) stressed protein.

Authors:  Marco Feligioni; Robert Nisticò
Journal:  Neuromolecular Med       Date:  2013-09-20       Impact factor: 3.843

4.  Cooperative interaction between protein inhibitor of activated signal transducer and activator of transcription-3 with epidermal growth factor receptor blockade in lung cancer.

Authors:  Amy Kluge; Snehal Dabir; Jeffrey Kern; David Nethery; Balazs Halmos; Patrick Ma; Afshin Dowlati
Journal:  Int J Cancer       Date:  2009-10-01       Impact factor: 7.396

5.  PIAS3, an inhibitor of STAT3, has intensively negative association with the survival of gastric cancer.

Authors:  Jingwu Li; Jianzhong Cui; Jinghua Zhang; Yuanting Liu; Longcai Han; Chunliang Jia; Jingyu Deng; Han Liang
Journal:  Int J Clin Exp Med       Date:  2015-01-15

6.  Regulation of MBD1-mediated transcriptional repression by SUMO and PIAS proteins.

Authors:  Matthew J Lyst; Xinsheng Nan; Irina Stancheva
Journal:  EMBO J       Date:  2006-10-26       Impact factor: 11.598

7.  The association and nuclear translocation of the PIAS3-STAT3 complex is ligand and time dependent.

Authors:  Snehal Dabir; Amy Kluge; Afshin Dowlati
Journal:  Mol Cancer Res       Date:  2009-11-10       Impact factor: 5.852

8.  Loss of protein inhibitors of activated STAT-3 expression in glioblastoma multiforme tumors: implications for STAT-3 activation and gene expression.

Authors:  Emily C Brantley; L Burton Nabors; G Yancey Gillespie; Youn-Hee Choi; Cheryl Ann Palmer; Keith Harrison; Kevin Roarty; Etty N Benveniste
Journal:  Clin Cancer Res       Date:  2008-08-01       Impact factor: 12.531

Review 9.  Sumoylation and human disease pathogenesis.

Authors:  Kevin D Sarge; Ok-Kyong Park-Sarge
Journal:  Trends Biochem Sci       Date:  2009-03-11       Impact factor: 13.807

10.  Small ubiquitin-like modifier 1-3 conjugation [corrected] is activated in human astrocytic brain tumors and is required for glioblastoma cell survival.

Authors:  Wei Yang; Liangli Wang; Gabriele Roehn; Robert D Pearlstein; Francis Ali-Osman; Hongjie Pan; Roland Goldbrunner; Matthew Krantz; Christoph Harms; Wulf Paschen
Journal:  Cancer Sci       Date:  2012-11-28       Impact factor: 6.716

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.